FDA DEVICE FACTS
Talos-C(HA) Cervical Intervertebral Body Fusion Devices
Meditech Spine, LLC
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Talos®‐C (HA) Cervical Intervertebral Body Fusion Devices are intervertebral body devices intended for use in skeletally mature patients with Degenerative Disc Disease (DDD) of the cervical spine at one level from C2‐T1. Cervical degenerative disc disease is defined as intractable radiculopathy and/or myelopathy with herniated disc and/or osteophyte formation on the posterior vertebral endplates producing symptomatic nerve root and/or spinal cord compression confirmed by history and radiographic studies. Talos®‐C (HA) Cervical IBF Devices are intended to be used with autologous bone graft to facilitate fusion. Non‐operative treatment prior to treatment with Talos®‐C (HA) Cervical Intervertebral Body Fusion Devices is six (6) weeks. Talos®‐C (HA) Cervical IBF Devices are to be implanted via an open anterior approach. Talos®‐C (HA) Cervical IBF Devices are also to be used with supplemental fixation.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。